JP2024501537A5 - - Google Patents
Info
- Publication number
- JP2024501537A5 JP2024501537A5 JP2023539966A JP2023539966A JP2024501537A5 JP 2024501537 A5 JP2024501537 A5 JP 2024501537A5 JP 2023539966 A JP2023539966 A JP 2023539966A JP 2023539966 A JP2023539966 A JP 2023539966A JP 2024501537 A5 JP2024501537 A5 JP 2024501537A5
- Authority
- JP
- Japan
- Prior art keywords
- nhr
- compound according
- optionally
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/PL2020/000099 WO2022146151A1 (en) | 2020-12-30 | 2020-12-30 | Novel compounds which bind to cereblon, and methods of use thereof |
| PLPCT/PL2020/000099 | 2020-12-30 | ||
| PCT/EP2021/087847 WO2022144416A1 (en) | 2020-12-30 | 2021-12-30 | Novel compounds which bind to cereblon, and methods of use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024501537A JP2024501537A (ja) | 2024-01-12 |
| JP2024501537A5 true JP2024501537A5 (https=) | 2025-01-09 |
| JP7853713B2 JP7853713B2 (ja) | 2026-04-30 |
Family
ID=74347684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023539966A Active JP7853713B2 (ja) | 2020-12-30 | 2021-12-30 | セレブロンに結合する新規な化合物、及びその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240307547A1 (https=) |
| EP (1) | EP4271670A1 (https=) |
| JP (1) | JP7853713B2 (https=) |
| KR (1) | KR20230128083A (https=) |
| CN (1) | CN116917275A (https=) |
| WO (2) | WO2022146151A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4584259A1 (en) | 2022-09-09 | 2025-07-16 | Innovo Therapeutics, Inc. | Ck1alpha and dual ck1alpha / gspt1 degrading compounds |
| WO2024167423A1 (en) * | 2023-02-07 | 2024-08-15 | Captor Therapeutics S.A. | Gspt1 degrader compounds |
| WO2025063888A1 (en) | 2023-09-19 | 2025-03-27 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025097090A1 (en) * | 2023-11-02 | 2025-05-08 | Neomorph, Inc. | Substituted (piperidin-4-yl)-1,5-naphthyridine and (piperidin-4-yl)quinoline derivatives and uses thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| CL2007002513A1 (es) | 2006-08-30 | 2008-04-04 | Celgene Corp Soc Organizada Ba | Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras. |
| ME02420B (me) | 2006-09-26 | 2016-09-20 | Celgene Corp | 5-supstituirani derivati kinazolinona kao sredstva protiv raka |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| KR102668696B1 (ko) * | 2012-01-12 | 2024-05-29 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| RU2738833C9 (ru) * | 2014-04-14 | 2022-02-28 | Арвинас, Оперэйшнз, Инк. | Имидные модуляторы протеолиза и способы их применения |
| EP3827836A1 (en) * | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| WO2016105518A1 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN109790143A (zh) | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109641874A (zh) * | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| EP3454856B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2018064589A1 (en) * | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
| CN110769822A (zh) | 2017-06-20 | 2020-02-07 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| EP4467143B1 (en) | 2017-07-10 | 2026-03-11 | Celgene Corporation | Method for preparing 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile |
| WO2022255888A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein |
-
2020
- 2020-12-30 WO PCT/PL2020/000099 patent/WO2022146151A1/en not_active Ceased
-
2021
- 2021-12-30 KR KR1020237026080A patent/KR20230128083A/ko active Pending
- 2021-12-30 WO PCT/EP2021/087847 patent/WO2022144416A1/en not_active Ceased
- 2021-12-30 JP JP2023539966A patent/JP7853713B2/ja active Active
- 2021-12-30 CN CN202180094397.3A patent/CN116917275A/zh active Pending
- 2021-12-30 EP EP21847732.1A patent/EP4271670A1/en active Pending
- 2021-12-30 US US18/259,868 patent/US20240307547A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024501537A5 (https=) | ||
| JP7527978B2 (ja) | カンプトテシンコンジュゲート | |
| JP7430643B2 (ja) | カンプトテシンペプチドコンジュゲート | |
| JP2020063241A5 (https=) | ||
| DE69409870T3 (de) | Heteroatom-substituierte Liganden und Metallkomplexe davon | |
| KR102492135B1 (ko) | 페길화된 카르필조밉 화합물 | |
| JP7074761B2 (ja) | 治療用デンドリマー | |
| CN114929284A (zh) | 喜树碱肽缀合物 | |
| JP2009537461A5 (https=) | ||
| JP2023504445A5 (https=) | ||
| JP2023512501A5 (https=) | ||
| JP2023504143A5 (https=) | ||
| US20120232169A1 (en) | Highly monodisperse branched peg-lipid conjugates | |
| JP2014503574A5 (https=) | ||
| JP2016516068A5 (https=) | ||
| CN114502201A (zh) | 靶向性树枝状体缀合物 | |
| US20230302144A1 (en) | Porphyrin Compounds and Compositions Useful for Treating Cancer | |
| JP2019513868A5 (https=) | ||
| JP2023538524A5 (https=) | ||
| JP2024509169A5 (https=) | ||
| EP3710063A1 (en) | Stable compositions of pegylated carfilzomib compounds | |
| JP2024519536A5 (https=) | ||
| JP2024529466A5 (https=) | ||
| CN112601740B (zh) | 用于治疗黑素瘤的放射性化合物及其用途 | |
| JP2022521474A5 (https=) |